Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DataLogic International Announces Results for Q3 2003
Thursday November 13, 5:30 am ET
- Revenues Increase 320% From Q2 2002 -
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- DataLogic International, Inc. (OTC Bulletin Board: DLGI - News; Berlin Stock Exchange: 779612 - News) today announced results for third quarter ended September 30, 2003. The Company's net revenues for the quarter increased $2,098,427, or 320%, to $2,753,728, as compared to $655,301 for the three months ended September 30, 2002.
ADVERTISEMENT
DataLogic's net profit for the three months ended September 30, 2003 increased $157,295 to $145,374, as compared to a loss of $11,921 for the same quarter one year ago. The increase in net income was primarily due to an increase in operating profits from more billable employees, sales of VoIP phones and airtime, and the Company's ability to better manage its general and overhead expenses.
"After a slight setback in last quarter's results due to merger and acquisition related expenses, we are back on our growth track," commented Derek Nguyen, the Company's CEO. "Our staff augmentation business is growing steadily with a consistent net income. We will continue to focus on securing additional governmental and commercial service contracts as a response to signs of increased spending."
"Our VoIP business is also showing steady growth," added Keith Nguyen, President of DataLogic. "Our distribution channels are expanding and IPN currently has several mid to large size clients that are in the testing phase of our systems. We are also working to introduce our products into major retail distribution channels. We expect these developments to result in significant sales increases in the near term."
About DataLogic International Inc.
DataLogic, operating through its wholly-owned subsidiary, DataLogic Consulting Inc., is a professional service company dedicated to solving its clients' business problems with technology-based solutions. Its services include SAS consultancy, project management, software development, Internet solutions, telecommunications/wireless integration, value added reselling/training and IT outsourcing. The Company also provides short and long term staffing solutions to IT clients and healthcare/medical providers.
Among the industries that DataLogic serves include Communications, Energy, Financial, Government, Healthcare, Manufacturing, Retail and Transportation. A partial list of the Company's current and previous clients include Alcon Labs, Amgen, Boeing, Compaq Computer, Cisco Systems, City of Houston, Commonwealth of Virginia, FDNY, FedEx, IBM Corp., International Paper, Kiboga Systems, Orange County Transportation Authority (OCTA), PacifiCare/RX Solutions, Phillips Petroleum, Prudential Healthcare, State of North Carolina, State of Rhode Island, SAS Institute and Sun Microsystems. For more information on DataLogic International, Inc., go to www.dlgi.com or contact Investor Relations at (888) 530-8228.
DataLogic International Announces Results for Q3 2003
Thursday November 13, 5:30 am ET
- Revenues Increase 320% From Q2 2002 -
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- DataLogic International, Inc. (OTC Bulletin Board: DLGI - News; Berlin Stock Exchange: 779612 - News) today announced results for third quarter ended September 30, 2003. The Company's net revenues for the quarter increased $2,098,427, or 320%, to $2,753,728, as compared to $655,301 for the three months ended September 30, 2002.
ADVERTISEMENT
DataLogic's net profit for the three months ended September 30, 2003 increased $157,295 to $145,374, as compared to a loss of $11,921 for the same quarter one year ago. The increase in net income was primarily due to an increase in operating profits from more billable employees, sales of VoIP phones and airtime, and the Company's ability to better manage its general and overhead expenses.
"After a slight setback in last quarter's results due to merger and acquisition related expenses, we are back on our growth track," commented Derek Nguyen, the Company's CEO. "Our staff augmentation business is growing steadily with a consistent net income. We will continue to focus on securing additional governmental and commercial service contracts as a response to signs of increased spending."
"Our VoIP business is also showing steady growth," added Keith Nguyen, President of DataLogic. "Our distribution channels are expanding and IPN currently has several mid to large size clients that are in the testing phase of our systems. We are also working to introduce our products into major retail distribution channels. We expect these developments to result in significant sales increases in the near term."
About DataLogic International Inc.
DataLogic, operating through its wholly-owned subsidiary, DataLogic Consulting Inc., is a professional service company dedicated to solving its clients' business problems with technology-based solutions. Its services include SAS consultancy, project management, software development, Internet solutions, telecommunications/wireless integration, value added reselling/training and IT outsourcing. The Company also provides short and long term staffing solutions to IT clients and healthcare/medical providers.
Among the industries that DataLogic serves include Communications, Energy, Financial, Government, Healthcare, Manufacturing, Retail and Transportation. A partial list of the Company's current and previous clients include Alcon Labs, Amgen, Boeing, Compaq Computer, Cisco Systems, City of Houston, Commonwealth of Virginia, FDNY, FedEx, IBM Corp., International Paper, Kiboga Systems, Orange County Transportation Authority (OCTA), PacifiCare/RX Solutions, Phillips Petroleum, Prudential Healthcare, State of North Carolina, State of Rhode Island, SAS Institute and Sun Microsystems. For more information on DataLogic International, Inc., go to www.dlgi.com or contact Investor Relations at (888) 530-8228.
DataLogic International Announces Results for Q3 2003
Thursday November 13, 5:30 am ET
- Revenues Increase 320% From Q2 2002 -
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- DataLogic International, Inc. (OTC Bulletin Board: DLGI - News; Berlin Stock Exchange: 779612 - News) today announced results for third quarter ended September 30, 2003. The Company's net revenues for the quarter increased $2,098,427, or 320%, to $2,753,728, as compared to $655,301 for the three months ended September 30, 2002.
ADVERTISEMENT
DataLogic's net profit for the three months ended September 30, 2003 increased $157,295 to $145,374, as compared to a loss of $11,921 for the same quarter one year ago. The increase in net income was primarily due to an increase in operating profits from more billable employees, sales of VoIP phones and airtime, and the Company's ability to better manage its general and overhead expenses.
"After a slight setback in last quarter's results due to merger and acquisition related expenses, we are back on our growth track," commented Derek Nguyen, the Company's CEO. "Our staff augmentation business is growing steadily with a consistent net income. We will continue to focus on securing additional governmental and commercial service contracts as a response to signs of increased spending."
"Our VoIP business is also showing steady growth," added Keith Nguyen, President of DataLogic. "Our distribution channels are expanding and IPN currently has several mid to large size clients that are in the testing phase of our systems. We are also working to introduce our products into major retail distribution channels. We expect these developments to result in significant sales increases in the near term."
About DataLogic International Inc.
DataLogic, operating through its wholly-owned subsidiary, DataLogic Consulting Inc., is a professional service company dedicated to solving its clients' business problems with technology-based solutions. Its services include SAS consultancy, project management, software development, Internet solutions, telecommunications/wireless integration, value added reselling/training and IT outsourcing. The Company also provides short and long term staffing solutions to IT clients and healthcare/medical providers.
Among the industries that DataLogic serves include Communications, Energy, Financial, Government, Healthcare, Manufacturing, Retail and Transportation. A partial list of the Company's current and previous clients include Alcon Labs, Amgen, Boeing, Compaq Computer, Cisco Systems, City of Houston, Commonwealth of Virginia, FDNY, FedEx, IBM Corp., International Paper, Kiboga Systems, Orange County Transportation Authority (OCTA), PacifiCare/RX Solutions, Phillips Petroleum, Prudential Healthcare, State of North Carolina, State of Rhode Island, SAS Institute and Sun Microsystems. For more information on DataLogic International, Inc., go to www.dlgi.com or contact Investor Relations at (888) 530-8228.
DLGI runing on great earning eom
DataLogic International Announces Results for Q3 2003
Thursday November 13, 5:30 am ET
- Revenues Increase 320% From Q2 2002 -
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- DataLogic International, Inc. (OTC Bulletin Board: DLGI - News; Berlin Stock Exchange: 779612 - News) today announced results for third quarter ended September 30, 2003. The Company's net revenues for the quarter increased $2,098,427, or 320%, to $2,753,728, as compared to $655,301 for the three months ended September 30, 2002.
ADVERTISEMENT
DataLogic's net profit for the three months ended September 30, 2003 increased $157,295 to $145,374, as compared to a loss of $11,921 for the same quarter one year ago. The increase in net income was primarily due to an increase in operating profits from more billable employees, sales of VoIP phones and airtime, and the Company's ability to better manage its general and overhead expenses.
"After a slight setback in last quarter's results due to merger and acquisition related expenses, we are back on our growth track," commented Derek Nguyen, the Company's CEO. "Our staff augmentation business is growing steadily with a consistent net income. We will continue to focus on securing additional governmental and commercial service contracts as a response to signs of increased spending."
"Our VoIP business is also showing steady growth," added Keith Nguyen, President of DataLogic. "Our distribution channels are expanding and IPN currently has several mid to large size clients that are in the testing phase of our systems. We are also working to introduce our products into major retail distribution channels. We expect these developments to result in significant sales increases in the near term."
About DataLogic International Inc.
DataLogic, operating through its wholly-owned subsidiary, DataLogic Consulting Inc., is a professional service company dedicated to solving its clients' business problems with technology-based solutions. Its services include SAS consultancy, project management, software development, Internet solutions, telecommunications/wireless integration, value added reselling/training and IT outsourcing. The Company also provides short and long term staffing solutions to IT clients and healthcare/medical providers.
Among the industries that DataLogic serves include Communications, Energy, Financial, Government, Healthcare, Manufacturing, Retail and Transportation. A partial list of the Company's current and previous clients include Alcon Labs, Amgen, Boeing, Compaq Computer, Cisco Systems, City of Houston, Commonwealth of Virginia, FDNY, FedEx, IBM Corp., International Paper, Kiboga Systems, Orange County Transportation Authority (OCTA), PacifiCare/RX Solutions, Phillips Petroleum, Prudential Healthcare, State of North Carolina, State of Rhode Island, SAS Institute and Sun Microsystems. For more information on DataLogic International, Inc., go to www.dlgi.com or contact Investor Relations at (888) 530-8228.
DLGI runing on great earning eom
DataLogic International Announces Results for Q3 2003
Thursday November 13, 5:30 am ET
- Revenues Increase 320% From Q2 2002 -
IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- DataLogic International, Inc. (OTC Bulletin Board: DLGI - News; Berlin Stock Exchange: 779612 - News) today announced results for third quarter ended September 30, 2003. The Company's net revenues for the quarter increased $2,098,427, or 320%, to $2,753,728, as compared to $655,301 for the three months ended September 30, 2002.
ADVERTISEMENT
DataLogic's net profit for the three months ended September 30, 2003 increased $157,295 to $145,374, as compared to a loss of $11,921 for the same quarter one year ago. The increase in net income was primarily due to an increase in operating profits from more billable employees, sales of VoIP phones and airtime, and the Company's ability to better manage its general and overhead expenses.
"After a slight setback in last quarter's results due to merger and acquisition related expenses, we are back on our growth track," commented Derek Nguyen, the Company's CEO. "Our staff augmentation business is growing steadily with a consistent net income. We will continue to focus on securing additional governmental and commercial service contracts as a response to signs of increased spending."
"Our VoIP business is also showing steady growth," added Keith Nguyen, President of DataLogic. "Our distribution channels are expanding and IPN currently has several mid to large size clients that are in the testing phase of our systems. We are also working to introduce our products into major retail distribution channels. We expect these developments to result in significant sales increases in the near term."
About DataLogic International Inc.
DataLogic, operating through its wholly-owned subsidiary, DataLogic Consulting Inc., is a professional service company dedicated to solving its clients' business problems with technology-based solutions. Its services include SAS consultancy, project management, software development, Internet solutions, telecommunications/wireless integration, value added reselling/training and IT outsourcing. The Company also provides short and long term staffing solutions to IT clients and healthcare/medical providers.
Among the industries that DataLogic serves include Communications, Energy, Financial, Government, Healthcare, Manufacturing, Retail and Transportation. A partial list of the Company's current and previous clients include Alcon Labs, Amgen, Boeing, Compaq Computer, Cisco Systems, City of Houston, Commonwealth of Virginia, FDNY, FedEx, IBM Corp., International Paper, Kiboga Systems, Orange County Transportation Authority (OCTA), PacifiCare/RX Solutions, Phillips Petroleum, Prudential Healthcare, State of North Carolina, State of Rhode Island, SAS Institute and Sun Microsystems. For more information on DataLogic International, Inc., go to www.dlgi.com or contact Investor Relations at (888) 530-8228.
PFCE 2 day run on good news eom
ROBE up 170%
GONT she going back up eom
GONT RUN HARD ON NEWS
GONT ROCKING HARD EOM
MDPA move on great earning eom
METCARE Announces Third Quarter Results
Monday November 10, 2:07 pm ET
Reports Third Quarter Net Income of $1.2 Million
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Nov. 10, 2003--Metropolitan Health Networks, Inc. (METCARE(SM)) (OTCBB:MDPA - News), a leading provider of healthcare services, today announced results for the three months ended September 30, 2003. The Company reported net income of $1.2 million on revenues of $35.7 million, compared to a net loss of $2.0 million and revenues of $34.6 million in the prior year quarter. On a basic per share basis, net income was $.03, compared to a loss of $.06 for the third quarter of 2002.
For the nine months ended September 30, 2003, the Company reported net income of $2.8 million on revenues of $108.4 million, compared to a net loss of $3.6 million and revenues of $105.2 million in the prior year period. On a basic per share basis, net income was $.08, compared to a loss of $.12 for the first nine months of 2002.
Income from continuing operations was nearly $1.7 million and $4.3 million for the three months and nine months ended September 30, 2003, respectively, compared to losses in the prior year periods. The 2003 results include losses from discontinued operations of $519,000 and $1.5 million for the third quarter and first nine months, respectively, compared to losses of $1.7 million and $2.4 million in the prior year periods. These losses reflect the operations of the Company's pharmacy division in 2003, and both the pharmacy and clinical laboratory in 2002.
With regard to the previously announced agreement to sell its Metcare Rx pharmacy unit, the Company reported that the parties to the transaction are working to complete the transaction. While there can be no assurance that the sale will be finalized, management believes that the completion of the deal is near.
Mike Earley, President and CEO, commented, "We continue to be pleased with our 2003 results. Not only have we maintained our profitability from the first two quarters, but also have continued to improve on a cash flow-basis, with related improvements in both working capital and net worth. These results have allowed us to make positive strides in addressing our various balance sheet issues, and in fact, we have reduced our total liabilities by more than $3 million during the first nine months of the year."
About Metropolitan Health Networks, Inc.
METCARE is a growing healthcare organization in Florida. The Company currently manages healthcare services for patients in South and Central Florida and is part of a network of physicians serving more than a million people from Miami to Daytona Beach on Florida's East Coast.
To learn more about Metropolitan Health Networks, Inc., please visit its website at http://www.metcare.com
Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to uncertainties and risks in part detailed in the company's Securities and Exchange Commission 10-K, 10-Q, S-8 and 8-K filings, that may cause actual results to materially differ from projections. Although Metropolitan Health Networks, Inc. believes its expectations are reasonable assumptions within the bounds of its knowledge of its businesses and operations; there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the company's ability to continue as a going concern; volatility of the company's stock and price; the ability to raise funds for working capital and acquisitions; access to borrowed or equity capital on favorable terms. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this report will, in fact, occur.
--------------------------------------------------------------------------------
Contact:
Metropolitan Health Networks, Inc., West Palm Beach
Michael M. Earley or David S. Gartner, 561/805-8500
EXTI buyer kicking in @1.09
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
Friday November 7, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI - News) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol® synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol® device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol® device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol® synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: Exten Industries Inc.
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
Friday November 7, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI - News) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol® synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol® device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol® device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol® synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: Exten Industries Inc.
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
Friday November 7, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI - News) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol® synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol® device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol® device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol® synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: Exten Industries Inc.
EXTI next leg up eom
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
Friday November 7, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI - News) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol® synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol® device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol® device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol® synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: Exten Industries Inc.
EXTI u/t on good news
Exten's Xenogenics Subsidiary Gets Notice of Liver Device Patent
Friday November 7, 8:30 am ET
WARWICK, R.I.--(BUSINESS WIRE)--Nov. 7, 2003--Exten Industries Inc. (Exten) (OTCBB:EXTI - News) announced today that its majority owned subsidiary, Xenogenics Corp. ("Xenogenics"), has received a notice of allowance from the U.S. Patent and Trade Office that its Sybiol® synthetic bio-liver device patent will be issued in the next few months.
Jerry Newmin, chairman and CEO of Exten, commented, "We have worked and waited a long time for this patent. It has the possibility of helping hundreds of thousands of people with liver trauma or insufficiency around the world. This original patent was based on the use of primary pig hepatocytes (liver cells). As there have been many design advances since the initial patent filing, including a switch to MultiCell's immortalized liver cells, we intend to file additional new patents covering recent improvements to this device. The team at MultiCell has been instrumental in building a promising new prototype that is ready for initial animal testing."
Xenogenic's synthetic bio-liver device has been re-designed to utilize the immortalized human liver cells lines developed by Exten's wholly owned subsidiary Multicell Technologies Inc. ("MultiCell"). Greg Szabo, president, added, "Our two subsidiaries have worked together to redesign and enhance the Sybiol® device around MultiCell's highly functional liver cell lines. Liver diseases affect about one out of every 10 Americans and that incidence appears to be increasing," he added. "Our Sybiol® device may well prove someday to be a useful tool in treating these patients."
The Sybiol synthetic bio-liver is an extra-corporeal device designed to support patients who are waiting for liver transplants, who are suffering from episodic liver disease caused by hepatitis, alcoholism, cancer, or from burn or toxic shock syndrome or other liver trauma. The device is designed to increase not only the life spans, but also the quality of life in afflicted patients.
About Exten:
Exten Industries Inc., through its two subsidiaries Xenogenics Corp. and MultiCell Technologies Inc., is engaged in developing liver-based products in the medical device, therapeutic and pharmaceutical testing arenas. Xenogenics is developing the Sybiol® synthetic bio-liver device. MultiCell provides hepatic (liver) cells and cell lines to pharmaceutical companies, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. Exten's corporate and research headquarters are in Warwick, RI. For more information about Exten and its subsidiaries, visit www.exten.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Exten Industries Inc., Warwick
Greg Szabo or Jerry Newmin, 401-738-7560
--------------------------------------------------------------------------------
Source: Exten Industries Inc.
BIPH moving great on today news eom
BIPH next leg up eom
camelToe' BIPH IMHO will do much better than CYPT eom
BIPH is runing hard eom
BIPH kabooooom lol.
GBMI U/T EOM
NOVL kaboooom eom
GBMI u/t
NOVL kabooooooom eom
congrats on this new board!!
GBMI low float, when volume kick in it will move fast eom
GBMI on sale .0025
BOCX nice eom
GBMI .0032X.0033 now.
Global Business Markets, Inc. Announces Focused Acquisition Campaign and Clarifies Acquisition of the Frulati Cafe and Bakery
Monday November 3, 8:32 am ET
LONGWOOD, Fla., Nov. 3 /PRNewswire-FirstCall/ -- Global Business Markets, Inc. (OTC Bulletin Board: GBMI - News), announced that it will continue to acquire companies in the Food and Beverage industry with an emphasis on Juice and Smoothie Bars in particular with an intent to facilitate a roll-up in that industry that will allow for these particular acquisitions to become franchise-able.
ADVERTISEMENT
Late last month the company announced its first acquisition of the Frulati Cafe and Bakery in Buffalo Grove, Illinois, since that announcement, the Company has not been able to complete its due diligence process and has converted the acquisition back over to an intent to purchase with a provision for another thirty to sixty day due diligence period to be in effect. This decision was made by company CEO, Edward Miers, following difficulties in final execution of the necessary documents at closing due to complications with a consultant, Suburban Capital Corporation of Addison, IL and its related associates, which were initially hired to solidify such transactions.
At this time the company is not commenting their intent to dissolve the consulting contract with Suburban Capital Corporation and its related associates, but has retained independent legal counsel to review past, present and future transactions and ensure proper compliance with all of the company's activities both from the corporate perspective and the regulatory perspective.
CEO, Edward Miers, said that "We believe that taking these precautions within the early stages of growing Global Business Markets, will only strengthen our core values and assist the company in becoming a more diligent and cohesive with regards to developing and growing underperforming companies.
About Global Business Markets Corporation
Global Business Markets Corporation is an entrepreneurial company focused on acquisitions and development of underperforming companies. The company is acquiring organizations that are in underserved markets that can benefit from the operational and managerial expertise that Global's executive and consulting staffs can provide. The company will launch its new corporate web site in mid to late November of this year. For more information please contact Edwards Miers, Chief Executive Officer, 3859 Wekiva Springs Road, Suite 302, Longwood, Florida 32779, phone 260.312.6789
This release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the company's current views with respect to future events that involve risks and uncertainties including uncertainties related to successful negotiations with other parties, oil and gas exploration risks, commodity price volatility, production levels, closing of transactions, capital availability, operational and other risks, uncertainties and factors described from time to time in the company's publicly available SEC reports. In light of these risks and uncertainties, the forward-looking events described in this release might not occur.
--------------------------------------------------------------------------------
Source: Global Business Markets, Inc.
Email this story - Set a News Alert
GBMI .0033 now eom
GBMI low float move great .0032x.0033
Press Release Source: Global Business Markets, Inc.
Global Business Markets, Inc. Announces Focused Acquisition Campaign and Clarifies Acquisition of the Frulati Cafe and Bakery
Monday November 3, 8:32 am ET
LONGWOOD, Fla., Nov. 3 /PRNewswire-FirstCall/ -- Global Business Markets, Inc. (OTC Bulletin Board: GBMI - News), announced that it will continue to acquire companies in the Food and Beverage industry with an emphasis on Juice and Smoothie Bars in particular with an intent to facilitate a roll-up in that industry that will allow for these particular acquisitions to become franchise-able.
ADVERTISEMENT
Late last month the company announced its first acquisition of the Frulati Cafe and Bakery in Buffalo Grove, Illinois, since that announcement, the Company has not been able to complete its due diligence process and has converted the acquisition back over to an intent to purchase with a provision for another thirty to sixty day due diligence period to be in effect. This decision was made by company CEO, Edward Miers, following difficulties in final execution of the necessary documents at closing due to complications with a consultant, Suburban Capital Corporation of Addison, IL and its related associates, which were initially hired to solidify such transactions.
At this time the company is not commenting their intent to dissolve the consulting contract with Suburban Capital Corporation and its related associates, but has retained independent legal counsel to review past, present and future transactions and ensure proper compliance with all of the company's activities both from the corporate perspective and the regulatory perspective.
CEO, Edward Miers, said that "We believe that taking these precautions within the early stages of growing Global Business Markets, will only strengthen our core values and assist the company in becoming a more diligent and cohesive with regards to developing and growing underperforming companies.
About Global Business Markets Corporation
Global Business Markets Corporation is an entrepreneurial company focused on acquisitions and development of underperforming companies. The company is acquiring organizations that are in underserved markets that can benefit from the operational and managerial expertise that Global's executive and consulting staffs can provide. The company will launch its new corporate web site in mid to late November of this year. For more information please contact Edwards Miers, Chief Executive Officer, 3859 Wekiva Springs Road, Suite 302, Longwood, Florida 32779, phone 260.312.6789
This release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the company's current views with respect to future events that involve risks and uncertainties including uncertainties related to successful negotiations with other parties, oil and gas exploration risks, commodity price volatility, production levels, closing of transactions, capital availability, operational and other risks, uncertainties and factors described from time to time in the company's publicly available SEC reports. In light of these risks and uncertainties, the forward-looking events described in this release might not occur.
--------------------------------------------------------------------------------
Source: Global Business Markets, Inc.
Email this story - Set a News Alert